Genvoya vs Symtuza
Side-by-side cost comparison based on Medicare Part D data
Genvoya
Elvitegravir/Cobicistat/Emtricitabine/TAF
Manufactured by Gilead
Symtuza
Darunavir/Cobicistat/Emtricitabine/TAF
Manufactured by Janssen
Symtuza costs 2% less per claim than Genvoya ($3,532.00 vs $3,619.00). A generic version of Symtuza is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Genvoya | Symtuza |
|---|---|---|
| Avg Cost Per Claim | $3,619.00 | $3,532.00 |
| Total Medicare Spending | $2.3B | $876.0M |
| Total Beneficiaries | 54,000 | 22,000 |
| Total Claims | 648,000 | 248,000 |
| Annual Cost/Patient | $43,426.00 | $39,818.00 |
| Year-over-Year Change | -8.4% | -2.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Gilead | Janssen |
| Condition | HIV | HIV |
| Generic Name | Elvitegravir/Cobicistat/Emtricitabine/TAF | Darunavir/Cobicistat/Emtricitabine/TAF |
Genvoya vs Symtuza: What the Data Shows
Genvoya (Elvitegravir/Cobicistat/Emtricitabine/TAF) and Symtuza (Darunavir/Cobicistat/Emtricitabine/TAF) are both used to treat hiv. Based on Medicare Part D data, Symtuza costs $3,532.00 per claim, which is 2% less than Genvoya at $3,619.00 per claim.
Medicare spent $2.3B on Genvoya and $876.0M on Symtuza. In terms of patient reach, Genvoya serves more beneficiaries (54,000 vs 22,000).
Year-over-year spending changed -8.4% for Genvoya and -2.4% for Symtuza.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Symtuza is cheaper at $3,532.00 per claim, compared to $3,619.00 for Genvoya. That makes Symtuza about 2% less expensive per claim based on Medicare Part D data.
Yes, both Genvoya and Symtuza are used to treat hiv. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Elvitegravir/Cobicistat/Emtricitabine/TAF and generic Darunavir/Cobicistat/Emtricitabine/TAF can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $2.3B on Genvoya covering 54,000 beneficiaries, and $876.0M on Symtuza covering 22,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.